• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Varex Imaging Corporation

    2/16/24 4:16:54 PM ET
    $VREX
    Industrial Machinery/Components
    Technology
    Get the next $VREX alert in real time by email
    S-8 1 forms-8cover.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 16, 2024
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
      ___________________________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     ___________________________________
    Varex Imaging Corporation
    (Exact name of Registrant as specified in its charter)
     ___________________________________
    Delaware
    81-3434516
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification Number)
    1678 S. Pioneer Road,
     Salt Lake City, Utah 84104
    (Address of principal executive offices) (Zip Code)
    Varex Imaging Corporation 2020 Omnibus Stock Plan, as Amended and Restated
    (Full title of the plan)
     ___________________________________

    Kimberley E. Honeysett
    Senior Vice President, Chief Legal Officer and Corporate Secretary
    Varex Imaging Corporation
    1678 S. Pioneer Road
    Salt Lake City, Utah 84104
    801-972-5000
    (Name, address and telephone number, including area code, of agent for service)

    Please send copies of all communications to:
    Brett Cooper
    Justin “JT” Ho
    Orrick, Herrington & Sutcliffe LLP
    405 Howard Street
    San Francisco, California 94105
    (415) 773-5700




    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

    Large Accelerated filer
    ☒
    Accelerated filer
    ☐
    Non-Accelerated filer
    ☐  
    Smaller reporting company
    ☐
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐

    2


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

        The documents containing the information specified in this Part I of Form S-8 have been and/or will be delivered to the participants holding the equity awards covered by this registration statement on Form S-8 (the “Registration Statement”) as required by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions of Part I of Form S-8, such documents are not required to be filed with the Securities and Exchange Commission (the “Commission”) as part of this Registration Statement. These documents, and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.
    Incorporation of Documents by Reference.
        Varex Imaging Corporation (the “Registrant”) hereby incorporated by reference in this Registration Statement the following documents previously filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”):
    (a)    the Registrant’s Annual Report on Form 10-K for the fiscal year ended September 29, 2023, filed on November 16, 2023 pursuant to Section 13(a) of the Exchange Act (the “2023 10-K”);
    (b)    all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and
    (d)     the description of the Registrant’s Common Stock contained in Exhibit 4.1, filed on November 16, 2023 with the 2023 10-K.
    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.
    Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.
    Description of Securities.
        Not applicable.

    Item 5.
    Interests of Named Experts and Counsel.
        Not applicable.

    Item 6.
    Indemnification of Directors and Officers.
    The Delaware General Corporation Law (the “DGCL”) authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties as directors, and the Registrant’s amended and restated certificate of incorporation includes such an exculpation provision. The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of the Registrant, or for serving at the Registrant’s request as a director or officer or another position at another corporation or enterprise, as the case may be. The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws also provide that the Registrant must indemnify and advance reasonable expenses to its directors
    3


    and officers, subject to its receipt of an undertaking from the indemnified party as may be required under the DGCL. The Registrant’s amended and restated certificate of incorporation expressly authorizes the Registrant to carry directors’ and officers’ insurance to protect the Registrant, its directors, officers and certain employees for some liabilities.
    The limitation of liability and indemnification provisions in the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against the Registrant’s directors, even though such an action, if successful, might otherwise benefit the Registrant and its stockholders. However, these provisions do not limit or eliminate the Registrant’s rights, or those of any stockholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director’s duty of care. The provisions do not alter the liability of directors under the federal securities laws.
    The Registrant has obtained director and officer liability insurance to cover liabilities directors and officers may incur in connection with their services to the Registrant.

    Item 7.
    Exemption from Registration Claimed.
        Not Applicable.
    Item 8.Exhibits.
        The following documents are filed as exhibits to this Registration Statement.
    Exhibit NumberDescription of Exhibit
    5.1*
    Opinion of Orrick, Herrington & Sutcliffe LLP
    23.1*
    Consent of Orrick, Herrington & Sutcliffe LLP (contained in Exhibit 5.1)
    23.2*
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    24*
    Power of Attorney (included as part of the signature pages of the Registration Statement)
    99.1*
    Varex Imaging Corporation 2020 Omnibus Stock Plan, as Amended and Restated
    107*
    Filing Fee Table
    *Filed herewith.

    Item 9.
    Undertakings.
    (a) The undersigned Registrant hereby undertakes:
    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and
    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by such paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is
    4


    incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

    5


    SIGNATURES
        Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Salt Lake City, State of Utah, on February 16, 2024.

    Varex Imaging Corporation
    By:/s/ Kimberley E. Honeysett
    Kimberley E. Honeysett
    Senior Vice President, General Counsel and Corporate Secretary
    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kimberley E. Honeysett, Sunny S. Sanyal, and Shubham Maheshwari, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8) with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in one or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    NameTitleDate
    /s/ Sunny S. SanyalPresident and Chief Executive Officer and Director
    (Principal Executive Officer)
    February 15, 2024
    Sunny S. Sanyal
    /s/ Shubham MaheshwariChief Financial Officer
    (Principal Financial Officer)
    February 15, 2024
    Shubham Maheshwari
    /s/ Walter M Rosebrough, Jr.DirectorFebruary 15, 2024
    Walter M Rosebrough, Jr.
    /s/ Kathleen L. BardwellDirectorFebruary 15, 2024
    Kathleen L. Bardwell
    /s/ Jocelyn D. ChertoffDirectorFebruary 15, 2024
    Jocelyn D. Chertoff
    /s/ Timothy E. GuertinDirectorFebruary 15, 2024
    Timothy E. Guertin
    /s/ Jay K. KunkelDirectorFebruary 15, 2024
    Jay K. Kunkel
    /s/ Christine A. TsingosDirectorFebruary 15, 2024
    Christine A. Tsingos
    6
    Get the next $VREX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VREX

    DatePrice TargetRatingAnalyst
    8/23/2024$21.00Buy
    B. Riley Securities
    10/12/2022$24.00Hold
    Jefferies
    More analyst ratings

    $VREX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Varex Imaging with a new price target

    B. Riley Securities initiated coverage of Varex Imaging with a rating of Buy and set a new price target of $21.00

    8/23/24 7:39:01 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Jefferies initiated coverage on Varex Imaging with a new price target

    Jefferies initiated coverage of Varex Imaging with a rating of Hold and set a new price target of $24.00

    10/12/22 9:08:06 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex Imaging upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Varex Imaging from Market Perform to Outperform and set a new price target of $35.50

    2/5/21 8:31:02 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kunkel Jay K. converted options into 8,483 shares, increasing direct ownership by 44% to 27,960 units (SEC Form 4)

    4 - Varex Imaging Corp (0001681622) (Issuer)

    2/10/26 4:04:29 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Director Bardwell Kathleen converted options into 8,483 shares, increasing direct ownership by 234% to 12,102 units (SEC Form 4)

    4 - Varex Imaging Corp (0001681622) (Issuer)

    2/9/26 4:14:10 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Director Chertoff Jocelyn D converted options into 8,483 shares, increasing direct ownership by 25% to 42,194 units (SEC Form 4)

    4 - Varex Imaging Corp (0001681622) (Issuer)

    2/9/26 4:15:00 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Varex Announces Financial Results for First Quarter Fiscal Year 2026

    Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the first quarter fiscal year 2026. Q1FY26 Summary Revenues $210 million GAAP gross margin 33% | Non-GAAP gross margin* 34% GAAP operating margin 7% | Non-GAAP operating margin* 9% GAAP net income $0.05 per diluted share | Non-GAAP net income* $0.19 per diluted share Cash outflow from operations of $16 million "We are pleased to report a solid start to fiscal 2026, with results toward the high-end of guidance. First quarter revenue of $210 million, increased 5% year-over-year. Growth in the quarter was driven by strength in our cargo systems business, which contributed to a 17% ye

    2/10/26 4:05:00 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex Schedules First Quarter Fiscal Year 2026 Earnings Release and Conference Call

    Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2026, following the close of regular trading on Tuesday, February 10, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from February 10th t

    1/27/26 9:05:00 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex to Participate in CJS Securities 26th Annual New Ideas for the New Year Conference

    Varex Imaging Corporation (NASDAQ:VREX) announced today that management is scheduled to present at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference. Management will be presenting on Wednesday, January 14, 2026 at 3:50pm ET. The webcast can be accessed here or on Varex's website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innov

    1/6/26 9:05:00 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    SEC Filings

    View All

    SEC Form 10-Q filed by Varex Imaging Corporation

    10-Q - Varex Imaging Corp (0001681622) (Filer)

    2/10/26 4:08:51 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex Imaging Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Varex Imaging Corp (0001681622) (Filer)

    2/10/26 4:06:33 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    SEC Form DEFA14A filed by Varex Imaging Corporation

    DEFA14A - Varex Imaging Corp (0001681622) (Filer)

    12/29/25 4:09:54 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Maheshwari Shubham bought $108,200 worth of shares (10,000 units at $10.82), increasing direct ownership by 22% to 56,063 units (SEC Form 4)

    4 - Varex Imaging Corp (0001681622) (Issuer)

    8/14/24 4:42:34 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Chief Financial Officer Maheshwari Shubham bought $98,897 worth of shares (9,007 units at $10.98), increasing direct ownership by 24% to 46,063 units (SEC Form 4)

    4 - Varex Imaging Corp (0001681622) (Issuer)

    8/12/24 4:33:04 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VREX
    Financials

    Live finance-specific insights

    View All

    Varex Announces Financial Results for First Quarter Fiscal Year 2026

    Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the first quarter fiscal year 2026. Q1FY26 Summary Revenues $210 million GAAP gross margin 33% | Non-GAAP gross margin* 34% GAAP operating margin 7% | Non-GAAP operating margin* 9% GAAP net income $0.05 per diluted share | Non-GAAP net income* $0.19 per diluted share Cash outflow from operations of $16 million "We are pleased to report a solid start to fiscal 2026, with results toward the high-end of guidance. First quarter revenue of $210 million, increased 5% year-over-year. Growth in the quarter was driven by strength in our cargo systems business, which contributed to a 17% ye

    2/10/26 4:05:00 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex Schedules First Quarter Fiscal Year 2026 Earnings Release and Conference Call

    Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2026, following the close of regular trading on Tuesday, February 10, 2026. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from February 10th t

    1/27/26 9:05:00 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025

    Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the fourth quarter and fiscal year 2025. Q4FY25 Summary Revenues $229 million GAAP gross margin 34% | Non-GAAP gross margin* 34% GAAP operating margin 9% | Non-GAAP operating margin* 10% GAAP net income $0.29 per diluted share | Non-GAAP net income* $0.37 per diluted share Cash flow from operations was $8 million FY25 Summary Revenues $845 million GAAP gross margin 34% | Non-GAAP gross margin* 35% GAAP operating margin (3)% | Non-GAAP operating margin* 9% GAAP net loss $(1.70) per diluted share | Non-GAAP net income* $0.90 per diluted share Cash flow from operations

    11/18/25 4:05:00 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $VREX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Varex Imaging Corporation

    SC 13G/A - Varex Imaging Corp (0001681622) (Subject)

    11/12/24 5:44:53 PM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13G/A filed by Varex Imaging Corporation

    SC 13G/A - Varex Imaging Corp (0001681622) (Subject)

    11/4/24 10:46:57 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13G/A filed by Varex Imaging Corporation

    SC 13G/A - Varex Imaging Corp (0001681622) (Subject)

    10/9/24 1:00:59 PM ET
    $VREX
    Industrial Machinery/Components
    Technology